Showing results (11-20 of 28) with videos related to
Sort By:
Pageof 3
Journal of Medicinal Chemistry|September 10, 2009
Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5)Frederick W Goldberg, Richard A Ward, Steven J Powell, et al.Molecular Pharmacology|November 22, 2018
Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor β Superfamily Type 1 ReceptorsLindsay C Spender, G John Ferguson, Gareth D Hughes, et al.ACS Chemical Biology|January 5, 2023
Chemical Biology Approaches Confirm MCT4 as the Therapeutic Target of a Cellular Optimized HitAarti Kawatkar, Roger A Clark, Lorna Hopcroft, et al.Journal of Medicinal Chemistry|January 16, 2014
Optimization of brain penetrant 11β-hydroxysteroid dehydrogenase type I inhibitors and in vivo testing in diet-induced obese miceFrederick W Goldberg, Alexander G Dossetter, James S Scott, et al.ACS Medicinal Chemistry Letters|December 21, 2016
Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 InhibitorsWilliam McCoull, Edward J Hennessy, Kevin Blades, et al.Journal of Medicinal Chemistry|December 16, 2022
Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for OncologyFrederick W Goldberg, Jason G Kettle, Gillian M Lamont, et al.Journal of Medicinal Chemistry|December 19, 2019
The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) InhibitorFrederick W Goldberg, M Raymond V Finlay, Attilla K T Ting, et al.ACS Medicinal Chemistry Letters|August 18, 2022
Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PKFrederick W Goldberg, Attilla K T Ting, David Beattie, et al.Journal for Immunotherapy of Cancer|April 7, 2022
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancerAlexey Revenko, Larissa S Carnevalli, Charles Sinclair, et al.Nature Communications|November 9, 2019
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activityJacqueline H L Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, et al.Pageof 3